Stockscreener 앱 받기
3.83
1.79%
-0.07
시장 영업 전:
3.83
전일 마감가:
$3.90
열려 있는:
$3.88
하루 거래량:
504.45K
Relative Volume:
0.83
시가총액:
$361.24M
수익:
$9.01M
순이익/손실:
$-99.72M
주가수익비율:
-0.844
EPS:
-4.5381
순현금흐름:
$-92.85M
1주 성능:
-3.28%
1개월 성능:
-5.20%
6개월 성능:
+3.51%
1년 성능:
+151.97%
1일 변동 폭
$3.74
$3.88
1주일 범위
$3.74
$4.48
52주 변동 폭
$1.35
$4.83
X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile
명칭
X 4 Pharmaceuticals Inc
전화
857-529-8300
주소
61 NORTH BEACON STREET, BOSTON, MA
Compare XFOR vs VRTX, REGN, ARGX, RVMD, ALNY
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
XFOR
X 4 Pharmaceuticals Inc
|
3.83 | 361.24M | 9.01M | -99.72M | -92.85M | -4.5381 |
VRTX
Vertex Pharmaceuticals Inc
|
486.03 | 123.36B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
678.94 | 71.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
857.97 | 53.68B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
179.18 | 38.09B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
283.15 | 37.80B | 4.29B | 577.22M | 641.34M | 4.2086 |
X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-09 | 개시 | Guggenheim | Buy |
| 2025-12-05 | 재개 | Stifel | Buy |
| 2023-12-12 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2023-08-30 | 재개 | B. Riley Securities | Buy |
| 2022-12-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-12-12 | 개시 | Piper Sandler | Overweight |
| 2019-12-23 | 개시 | Oppenheimer | Outperform |
| 2019-12-18 | 개시 | ROTH Capital | Buy |
| 2019-12-09 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-12-05 | 개시 | B. Riley FBR | Buy |
| 2019-06-07 | 개시 | Stifel | Buy |
| 2019-06-05 | 개시 | Cowen | Outperform |
모두보기
X 4 Pharmaceuticals Inc 주식(XFOR)의 최신 뉴스
Form 4 Adial Pharmaceuticals Inc For: 16 July By Investing.com - Investing.com Canada
Form 4 Phathom Pharmaceuticals Inc For: 16 July By Investing.com - Investing.com Nigeria
Form 4 Shuttle Pharmaceuticals Inc For: 15 July By Investing.com - Investing.com Canada
ELTP vs. CPIX: Which Pharma Stock Is the Better Buy Right Now? - TradingView
Form 4 Armata Pharmaceuticals Inc For: 14 July By Investing.com - Investing.com Nigeria
Form 4 Eton Pharmaceuticals Inc For: 14 July By Investing.com - Investing.com Canada
Form 4 Shuttle Pharmaceuticals Inc For: 13 July By Investing.com - Investing.com Canada
Form 4 Adial Pharmaceuticals Inc For: 13 July By Investing.com - Investing.com Canada
XFOR Q1 2026 Earnings: Narrower-Than-Expected Loss Boosts SentimentAdjusted Earnings Analysis - dars.gov.et
Layoff Tracker: EMD Serono may trim R&D workforce by up to 70 - BioSpace
X4 Pharmaceuticals (XFOR) Q1 2026 earnings summary - Quartr
X4 Pharmaceuticals (XFOR) Proxy filing Summary - Quartr
X4 Pharmaceuticals (XFOR) Q4 2025 earnings summary - Quartr
X4 Pharmaceuticals (XFOR) Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary - Quartr
X4 Pharmaceuticals (XFOR) Corporate presentation Summary - Quartr
X4 Pharmaceuticals (XFOR) Registration filing Summary - Quartr
X4 Pharmaceuticals (XFOR) Rallies 11.36% as Positive Sentiment Drives Price Above Key SupportProfit Surge Picks - Bölüm Sonu Canavarı
Form 4 Rigel Pharmaceuticals Inc For: 10 July By Investing.com - Investing.com Nigeria
Form 4 Sonoma Pharmaceuticals Inc For: 9 July By Investing.com - Investing.com South Africa
Form 4 Shuttle Pharmaceuticals Inc For: 9 July By Investing.com - Investing.com Nigeria
Form 4 Ironwood Pharmaceuticals Inc For: 9 July By Investing.com - Investing.com South Africa
Form 4 Recursion Pharmaceuticals Inc For: 9 July By Investing.com - Investing.com Nigeria
Form 4 Ionis Pharmaceuticals Inc For: 9 July By Investing.com - Investing.com Nigeria
X4 Pharmaceuticals stock focuses on rare disease pipeline after Nasdaq listing - ad-hoc-news.de
Form 4 Mirum Pharmaceuticals Inc For: 8 July By Investing.com - Investing.com Nigeria
Form 4 Oric Pharmaceuticals Inc For: 8 July By Investing.com - Investing.com South Africa
Is BBIO Stock a Buy Now or Too Expensive for the Risk Ahead - TradingView
X4 Pharmaceuticals (XFOR) Stifel 2024 Healthcare Conference Summary - Quartr
Form 4 Eton Pharmaceuticals Inc For: 7 July By Investing.com - Investing.com Nigeria
Form 4 Xeris Pharmaceuticals Inc For: 7 July By Investing.com - Investing.com Nigeria
Form 4 Crinetics Pharmaceuticals Inc For: 7 July By Investing.com - Investing.com Nigeria
Form 4 Regeneron Pharmaceuticals Inc For: 7 July By Investing.com - Investing.com Nigeria
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Form 4 Vertex Pharmaceuticals Inc For: 7 July By Investing.com - Investing.com Canada
Form 4 ANI Pharmaceuticals Inc For: 6 July By Investing.com - Investing.com Nigeria
Form 4 Ionis Pharmaceuticals Inc For: 6 July By Investing.com - Investing.com Nigeria
Price to earnings forward of X4 Pharmaceuticals, Inc. – NASDAQ:XFOR - TradingView
Enterprise value to revenue forward of X4 Pharmaceuticals, Inc. – LS:A3E4QR - TradingView
XFOR Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Price to sales forward of X4 Pharmaceuticals, Inc. – NASDAQ:XFOR - TradingView
Form 4 Shuttle Pharmaceuticals Inc For: 1 July By Investing.com - Investing.com Canada
X4 Pharmaceuticals CFO David Kirske sells $36,428 in common stock By Investing.com - Investing.com Canada
Form 4 X4 Pharmaceuticals Inc For: 1 July By Investing.com - Investing.com Canada
Form 4 Processa Pharmaceuticals Inc For: 1 July By Investing.com - Investing.com Canada
X4 Pharmaceuticals (XFOR) CFO sells 8,543 shares to cover RSU tax - Stock Titan
Director Kelly Gold granted 110,000 X4 Pharmaceuticals (XFOR) stock options at $4.085 - Stock Titan
X4 Pharmaceuticals (XFOR) director Gold Kelly files initial Form 3 ownership - Stock Titan
Kelly Gold joins X4 Pharmaceuticals (Nasdaq: XFOR) board and Audit Committee - Stock Titan
X4 Pharmaceuticals Announces Appointment of Kelly Gold as an Independent Director and Member of the Audit Committee, Effective July 1, 2026 - marketscreener.com
Form 4 Adial Pharmaceuticals Inc For: 1 July By Investing.com - Investing.com Canada
60 Degrees Pharmaceuticals Announces Positive Recommendation from Data Safety Monitoring Board for B-FREE Phase 2 Study of Tafenoquine for Treatment of Chronic Babesiosis Patients with Severe Fatigue - The Manila Times
X 4 Pharmaceuticals Inc (XFOR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
X 4 Pharmaceuticals Inc 주식 (XFOR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| KIRSKE DAVID | Chief Financial Officer |
May 12 '26 |
Sale |
4.29 |
16,961 |
72,820 |
176,293 |
1.36%
2.75%
자본화:
|
볼륨(24시간):